Sign in Subscribe
Health care industry

Aclarion Appoints Greg Gould as Chief Financial Officer, Driving Growth and Value Creation

Strategic Insights

— 1 min read

Brent Ness, CEO of Aclarion, stated that Greg Gould's expertise in driving growth, capital strategies, and financial leadership will be invaluable in executing the company's vision of making Nociscan more widely available to physicians and patients with chronic low back pain. Aclarion's Nociscan solution is a SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes.

Key Takeaways:

  • Greg Gould, a 30-year finance veteran, brings extensive experience in raising capital, driving revenue growth, and scaling operations to $500M.
  • He has raised over $450 million in public company debt and equity offerings and led over ten acquisitions throughout his career.
  • Gould has a proven track record of building and streamlining accounting, finance, and administrative functions, with expertise spanning financial controllership, planning and analysis, compliance, consolidation, integration, and auditing.
  • He has successfully sold three publicly-traded companies and guided three organizations through uplistings to Nasdaq.
  • Appointed to replace long-time CFO John Lorbiecki, who will retire.
  • Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians identify painful and nonpainful discs in the lumbar spine.
  • Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes.
  • Chronic low back pain (cLBP) affects approximately 266 million people worldwide, making it a significant global healthcare problem.

Statistics:

  • Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
  • Chronic low back pain (cLBP) affects approximately 266 million people worldwide.
  • Nociscan quantifies chemical biomarkers demonstrated to be associated with disc pain, potentially driving better surgical outcomes.
  • Greg Gould raised over $450 million in public company debt and equity offerings throughout his career.

Sources:

  • GlobeNewswire: "Aclarion, Inc. Appoints Greg Gould as Chief Financial Officer".
  • Aclarion's website and investment prospectus.

Read more